BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dalakas MC, Alexopoulos H, Spaeth PJ. Complement in neurological disorders and emerging complement-targeted therapeutics. Nat Rev Neurol 2020;16:601-17. [PMID: 33005040 DOI: 10.1038/s41582-020-0400-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 De Marchi F, Munitic I, Amedei A, Berry JD, Feldman EL, Aronica E, Nardo G, Van Weehaeghe D, Niccolai E, Prtenjaca N, Sakowski SA, Bendotti C, Mazzini L. Interplay between immunity and amyotrophic lateral sclerosis: Clinical impact. Neurosci Biobehav Rev 2021;127:958-78. [PMID: 34153344 DOI: 10.1016/j.neubiorev.2021.06.027] [Reference Citation Analysis]
2 Schmetzer O, Lakin E, Roediger B, Duchow A, Asseyer S, Paul F, Siebert N. Anti-aquaporin 4 IgG Is Not Associated With Any Clinical Disease Characteristics in Neuromyelitis Optica Spectrum Disorder. Front Neurol 2021;12:635419. [PMID: 33776892 DOI: 10.3389/fneur.2021.635419] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Dalakas MC. Update on Intravenous Immunoglobulin in Neurology: Modulating Neuro-autoimmunity, Evolving Factors on Efficacy and Dosing and Challenges on Stopping Chronic IVIg Therapy. Neurotherapeutics 2021. [PMID: 34766257 DOI: 10.1007/s13311-021-01108-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Keller CW, Pawlitzki M, Wiendl H, Lünemann JD. Fc-Receptor Targeted Therapies for the Treatment of Myasthenia gravis. Int J Mol Sci 2021;22:5755. [PMID: 34071155 DOI: 10.3390/ijms22115755] [Reference Citation Analysis]
5 Jin Y, Li D, Sun T, Du Y, Gao Y, Ding R, Ji W, Zhang W, Yang H, Chen S, Duan G. Pathological Features of Enterovirus 71-Associated Brain and Lung Damage in Mice Based on Quantitative Proteomic Analysis. Front Microbiol 2021;12:663019. [PMID: 34220748 DOI: 10.3389/fmicb.2021.663019] [Reference Citation Analysis]
6 Chen Y, Chu JMT, Chang RCC, Wong GTC. The Complement System in the Central Nervous System: From Neurodevelopment to Neurodegeneration. Biomolecules 2022;12:337. [PMID: 35204837 DOI: 10.3390/biom12020337] [Reference Citation Analysis]
7 Stathopoulos P, Dalakas MC. Autoimmune Neurogenic Dysphagia. Dysphagia 2021. [PMID: 34226958 DOI: 10.1007/s00455-021-10338-9] [Reference Citation Analysis]
8 Shestopalov VI, Spurlock M, Gramlich OW, Kuehn MH. Immune Responses in the Glaucomatous Retina: Regulation and Dynamics. Cells 2021;10:1973. [PMID: 34440742 DOI: 10.3390/cells10081973] [Reference Citation Analysis]
9 Lee H, Sung EJ, Seo S, Min EK, Lee JY, Shim I, Kim P, Kim TY, Lee S, Kim KT. Integrated multi-omics analysis reveals the underlying molecular mechanism for developmental neurotoxicity of perfluorooctanesulfonic acid in zebrafish. Environ Int 2021;157:106802. [PMID: 34358914 DOI: 10.1016/j.envint.2021.106802] [Reference Citation Analysis]
10 Dalmau J, Dalakas MC, Kolson DL, Paul F, Zamvil SS. N2 year in review. Neurol Neuroimmunol Neuroinflamm 2021;8:e925. [PMID: 33411673 DOI: 10.1212/NXI.0000000000000925] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Budding K, Johansen LE, Van de Walle I, Dijkxhoorn K, de Zeeuw E, Bloemenkamp LM, Bos JW, Jansen MD, Curial CAD, Silence K, de Haard H, Blanchetot C, Van de Ven L, Leusen JHW, Pasterkamp RJ, van den Berg LH, Hack CE, Boross P, van der Pol WL. Anti-C2 Antibody ARGX-117 Inhibits Complement in a Disease Model for Multifocal Motor Neuropathy. Neurol Neuroimmunol Neuroinflamm 2022;9:e1107. [PMID: 34759020 DOI: 10.1212/NXI.0000000000001107] [Reference Citation Analysis]
12 Keller CW, Lopez JA, Wendel EM, Ramanathan S, Gross CC, Klotz L, Reindl M, Dale RC, Wiendl H, Rostásy K, Brilot F, Lünemann JD. Reply to "Investigating the Immunopathogenic Mechanisms Underlying MOGAD". Ann Neurol 2021. [PMID: 34862658 DOI: 10.1002/ana.26278] [Reference Citation Analysis]
13 Shinjyo N, Hikosaka K, Kido Y, Yoshida H, Norose K. Toxoplasma Infection Induces Sustained Up-Regulation of Complement Factor B and C5a Receptor in the Mouse Brain via Microglial Activation: Implication for the Alternative Complement Pathway Activation and Anaphylatoxin Signaling in Cerebral Toxoplasmosis. Front Immunol 2020;11:603924. [PMID: 33613523 DOI: 10.3389/fimmu.2020.603924] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Sechi E, Flanagan EP. Antibody-Mediated Autoimmune Diseases of the CNS: Challenges and Approaches to Diagnosis and Management. Front Neurol 2021;12:673339. [PMID: 34305787 DOI: 10.3389/fneur.2021.673339] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Perego C, Di Cairano ES, Galli A, Moretti S, Bazzicaluppi E, Centonze VF, Gastaldelli A, Assi E, Fiorina P, Federici M, Porzio O, Bertuzzi F, Davalli AM, Folli F. Autoantibodies Against the Glial Glutamate Transporter GLT1/EAAT2 in Type 1 Diabetes Mellitus. Clues to novel immunological and non-immunological therapies. Pharmacological Research 2022. [DOI: 10.1016/j.phrs.2022.106130] [Reference Citation Analysis]
16 Tremblay MÈ. Microglial functional alteration and increased diversity in the challenged brain: Insights into novel targets for intervention. Brain Behav Immun Health 2021;16:100301. [PMID: 34589793 DOI: 10.1016/j.bbih.2021.100301] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Berkowitz S, Chapman J, Dori A, Gofrit SG, Maggio N, Shavit-Stein E. Complement and Coagulation System Crosstalk in Synaptic and Neural Conduction in the Central and Peripheral Nervous Systems. Biomedicines 2021;9:1950. [PMID: 34944766 DOI: 10.3390/biomedicines9121950] [Reference Citation Analysis]
18 Li J, Zhang G, Sun Q, Zhang K, Lu H, Xiao J, Han Z, Zhao H, Xu W, Zhang Y, Liu Z. Pathological Characteristics of Echovirus 30 Infection in a Mouse Model. J Virol 2022;:e0012922. [PMID: 35420443 DOI: 10.1128/jvi.00129-22] [Reference Citation Analysis]
19 Briani C, Visentin A. Therapeutic Monoclonal Antibody Therapies in Chronic Autoimmune Demyelinating Neuropathies. Neurotherapeutics 2022. [PMID: 35349079 DOI: 10.1007/s13311-022-01222-x] [Reference Citation Analysis]
20 Waszczuk K, Kucharska-mazur J, Tyburski E, Rek-owodziń K, Plichta P, Rudkowski K, Podwalski P, Grąźlewski T, Mak M, Misiak B, Michalczyk A, Tarnowski M, Sielatycka K, Szczęśniak A, Łuczkowska K, Dołęgowska B, Budkowska M, Ratajczak MZ, Samochowiec J. Psychopathology and Stem Cell Mobilization in Ultra-High Risk of Psychosis and First-Episode Psychosis Patients. IJERPH 2022;19:6001. [DOI: 10.3390/ijerph19106001] [Reference Citation Analysis]
21 Łuczkowska K, Rutka M, Rogińska D, Paczkowska E, Baumert B, Milczarek S, Górska M, Kulig P, Osękowska B, Janowski M, Safranow K, Sommerfeld K, Borowiecka E, Zawodny P, Koclęga A, Helbig G, Machaliński B. The Potential Role of Proinflammatory Cytokines and Complement Components in the Development of Drug-Induced Neuropathy in Patients with Multiple Myeloma. J Clin Med 2021;10:4584. [PMID: 34640602 DOI: 10.3390/jcm10194584] [Reference Citation Analysis]
22 Gytz Olesen H, Michailidou I, Zelek WM, Vreijling J, Ruizendaal P, de Klein F, Marquart JA, Kuipers TB, Mei H, Zhang Y, Ahasan M, Johnson KK, Wang Y, Morgan BP, van Dijk M, Fluiter K, Andersen GR, Baas F. Development, Characterization, and in vivo Validation of a Humanized C6 Monoclonal Antibody that Inhibits the Membrane Attack Complex. J Innate Immun 2022;:1-21. [PMID: 35551129 DOI: 10.1159/000524587] [Reference Citation Analysis]
23 Dalakas MC. Complement in autoimmune inflammatory myopathies, the role of myositis-associated antibodies, COVID-19 associations, and muscle amyloid deposits. Expert Rev Clin Immunol 2022;:1-11. [PMID: 35323101 DOI: 10.1080/1744666X.2022.2054803] [Reference Citation Analysis]
24 Asavapanumas N, Tradtrantip L, Verkman AS. Targeting the complement system in neuromyelitis optica spectrum disorder. Expert Opin Biol Ther 2021;21:1073-86. [PMID: 33513036 DOI: 10.1080/14712598.2021.1884223] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Wu CL, Chao CH, Lin SW, Chien YY, Huang WY, Weng WC, Su FC, Wei YC. Case Report: Plasma Biomarkers Reflect Immune Mechanisms of Guillain-Barré Syndrome. Front Neurol 2021;12:720794. [PMID: 34539561 DOI: 10.3389/fneur.2021.720794] [Reference Citation Analysis]
26 Schneider-Gold C, Gilhus NE. Advances and challenges in the treatment of myasthenia gravis. Ther Adv Neurol Disord 2021;14:17562864211065406. [PMID: 34987614 DOI: 10.1177/17562864211065406] [Reference Citation Analysis]
27 Li Z, Zhang W, Gao F, Shen Y, Kang D, Tang Q. Different Complement Activation Pathways Underly Cognitive Impairment and Type 2 Diabetes Mellitus Combined With Cognitive Impairment. Front Aging Neurosci 2022;14:810335. [DOI: 10.3389/fnagi.2022.810335] [Reference Citation Analysis]
28 Francelle L, Mazzulli JR. Neuroinflammation in aucher disease, neuronal ceroid lipofuscinosis, and commonalities with Parkinson’s disease. Brain Research 2022. [DOI: 10.1016/j.brainres.2022.147798] [Reference Citation Analysis]
29 Yüceer H, Gezen Ak D, Benbir Şenel G, Dursun E, Yılmaz V, Karadeniz D, Tüzün E, Küçükali Cİ. Classical complement pathway factor alterations in narcolepsy. Acta Neuropsychiatr 2022;:1-8. [PMID: 35034679 DOI: 10.1017/neu.2021.42] [Reference Citation Analysis]
30 Lee JD, Woodruff TM. The emerging role of complement in neuromuscular disorders. Semin Immunopathol 2021;43:817-28. [PMID: 34705082 DOI: 10.1007/s00281-021-00895-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 McCombe JA, Pittock SJ. Anti-complement Agents for Autoimmune Neurological Disease. Neurotherapeutics 2022. [PMID: 35553024 DOI: 10.1007/s13311-022-01223-w] [Reference Citation Analysis]
32 Šimončičová E, Gonçalves de Andrade E, Vecchiarelli HA, Awogbindin IO, Delage CI, Tremblay MÈ. Present and future of microglial pharmacology. Trends Pharmacol Sci 2022:S0165-6147(21)00223-6. [PMID: 35031144 DOI: 10.1016/j.tips.2021.11.006] [Reference Citation Analysis]
33 Howard JF Jr, Vissing J, Gilhus NE, Leite MI, Utsugisawa K, Duda PW, Farzaneh-Far R, Murai H, Wiendl H. Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody-Positive Generalized Myasthenia Gravis. Expert Opin Investig Drugs 2021;30:483-93. [PMID: 33792453 DOI: 10.1080/13543784.2021.1897567] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
34 Garlich J, Cinier M, Chevrel A, Perrocheau A, Eyerman DJ, Orme M, Kitten O, Scheibler L. Discovery of APL-1030, a Novel, High-Affinity Nanofitin Inhibitor of C3-Mediated Complement Activation. Biomolecules 2022;12:432. [DOI: 10.3390/biom12030432] [Reference Citation Analysis]
35 Wu KM, Zhang YR, Huang YY, Dong Q, Tan L, Yu JT. The role of the immune system in Alzheimer's disease. Ageing Res Rev 2021;70:101409. [PMID: 34273589 DOI: 10.1016/j.arr.2021.101409] [Reference Citation Analysis]
36 Zeng R, Glaubitz S, Schmidt J. Antibody Therapies in Autoimmune Inflammatory Myopathies: Promising Treatment Options. Neurotherapeutics 2022. [PMID: 35394612 DOI: 10.1007/s13311-022-01220-z] [Reference Citation Analysis]
37 Plomp JJ, Huijbers MGM, Verschuuren JJGM, Borodovsky A. A bioassay for neuromuscular junction-restricted complement activation by myasthenia gravis acetylcholine receptor antibodies. J Neurosci Methods 2022;:109551. [PMID: 35247492 DOI: 10.1016/j.jneumeth.2022.109551] [Reference Citation Analysis]
38 Querol LA, Hartung HP, Lewis RA, van Doorn PA, Hammond TR, Atassi N, Alonso-Alonso M, Dalakas MC. The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy: Implications for Complement-Targeted Therapies. Neurotherapeutics 2022. [PMID: 35378684 DOI: 10.1007/s13311-022-01221-y] [Reference Citation Analysis]
39 Giorgio C, Zippoli M, Cocchiaro P, Castelli V, Varrassi G, Aramini A, Allegretti M, Brandolini L, Cesta MC. Emerging Role of C5 Complement Pathway in Peripheral Neuropathies: Current Treatments and Future Perspectives. Biomedicines 2021;9:399. [PMID: 33917266 DOI: 10.3390/biomedicines9040399] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Yan XJ, Li YB, Liu W, Wu HY, Yu GF. Elevated Serum Complement C1q Levels After Traumatic Brain Injury and Its Association with Poor Prognosis. Neuropsychiatr Dis Treat 2022;18:47-55. [PMID: 35035218 DOI: 10.2147/NDT.S348682] [Reference Citation Analysis]
41 Pahan S, Pahan K. Can cinnamon spice down autoimmune diseases? J Clin Exp Immunol 2020;5:252-8. [PMID: 33294884 DOI: 10.33140/jcei.05.06.01] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
42 Jiang H, Niu F, Zheng Y, Xu Y. CART mitigates oxidative stress and DNA damage in memory deficits of APP/PS1 mice via upregulating β‑amyloid metabolism‑associated enzymes. Mol Med Rep 2021;23:280. [PMID: 33604684 DOI: 10.3892/mmr.2021.11919] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]